Evaluation of the Effect of Triamcinolone in Vitiligo patients

Comparison of the efficacy and safety of intralesional triamcinolone injection with placebo in treatment-resistant depigmented patches of acral areas in vitiligo patients referred to Loghman Hakim Hospital between 2025-2026

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251213068314N1

Enrollment

Registered

2026-02-18

Start date

2025-12-26

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo.

Interventions

Intervention 1: Intervention group: Intervention group: After obtaining the patient's consent, 2 patches of approximately the same size are selected on the upper or lower limb. In one of the patches,

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: vitiligo patients with treatment resistant depigmented patches on acral areas

Exclusion criteria

Exclusion criteria: Dissatisfaction at any stage of the study, pregnancy, breastfeeding, active infection at the intended injection site

Design outcomes

Primary

Measure	Time frame
Pigmentation returns to depigmented patches in vitiligo patients. Timepoint: After each injection, which was given in 4 doses at one month intervals, and after 2 months from the last injection. Method of measurement: Comparison of before and after injection images.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam sadat Ahmadi

Shahid Beheshti University of Medical Sciences

dr.maryam.ahmadi3185@gmail.com+98 21 5541 9005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026